PURSUING A POTENTIALLY TRANSFORMATIVE CANCER TREATMENT APPROACH

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR TTM) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

We BELIEVE

We believe the next revolution in cancer treatment is the development of AlloCAR TTM therapies engineered from the T cells of healthy donors. These off-the-shelf CAR T therapies enhanced by gene editing could be the next most important breakthrough in the field. Our mission is to catalyze this immune cell therapy approach and deliver AlloCARsTM to patients with hematologic cancers and solid tumors to make a difference in their lives.

 

Our HISTORY

April 2018 – Allogene acquires Pfizer’s allogeneic CAR T portfolio and closes one of the largest Series A rounds in biotechnology history of $300M from a premier investment consortium that included Two River, TPG, Vida Ventures, Bellco Capital, the University of California Office of the Chief Investment Officer, Gilead and Pfizer

September 2018 – Completes $120 million private financing

October 2018 – Public company debut, raising $372.6 million in gross proceeds in the second largest biotechnology IPO of 2018

December 2018 –100th employee joins

January 2019 – First Investigational New Drug Application (IND) clears, setting the stage for the Phase 1/2 ALPHA clinical trial of ALLO-501, an anti-CD19 AlloCAR T™ therapy for patients with relapsed/refractory non-Hodgkin lymphoma

February 2019 – Kicks off process in Newark, California to build state-of-the-art AlloCAR T manufacturing facility

May 2019 – Initiates first Phase 1 clinical trial with the ALLO-501 ALPHA study for patients with relapsed/refractory non-Hodgkin lymphoma

May 2019 – Receives FDA IND clearance for the UNIVERSAL study of ALLO-715, an AlloCAR T™ therapy targeting BCMA for patients with relapsed/refractory multiple myeloma